Goldman Sachs
CDAK

Goldman Sachs’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Goldman Sachs’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21,853
Closed -$63K – 6723
2022
Q2 		$63K Sell
21,853
-13,713
-39% -$48.1K ﹤0.01% 5979
2022
Q1 		$223K Buy
+35,566
New +$223K ﹤0.01% 5823

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Goldman Sachs's CDAK Position: Q3 2022 in Review

Goldman Sachs sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q3 2022, closing a stake of 21,853 shares — an estimated $63K sold.

Goldman Sachs first reported a position in CDAK in Q1 2022 and held it in 2 quarters. The position peaked at $223K in Q1 2022. 48 funds tracked by Wall St. Rank hold CDAK as of Q3 2022.

  • Goldman Sachs reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Goldman Sachs sold 21,853 Codiak BioSciences, Inc. Common Stock shares in Q3 2022, an estimated $63K.
  • Goldman Sachs first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Goldman Sachs's Codiak BioSciences, Inc. Common Stock position peaked at $223K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q3 2022.

Based on Goldman Sachs's 13F filing for Q3 2022, filed 14 Nov 2022.